NasdaqGS:BIIBBiotechs
Did China’s At‑Home LEQEMBI Review Just Shift Biogen's (BIIB) Alzheimer’s Care Investment Narrative?
Biogen and Eisai previously announced that China’s National Medical Products Administration accepted their Biologics License Application for a subcutaneous, once-weekly at-home formulation of Alzheimer’s therapy LEQEMBI, advancing it into formal regulatory review.
This move could materially change how Alzheimer’s care is delivered in China by shifting treatment from hospital-based infusions to more convenient at-home self-administration.
Next, we’ll explore how the potential for at-home...